Affiliations: [a] Research Memory Center (CMRR), CHU Besançon, Besançon, France | [b] Research Memory Center (CMRR) Paris-Nord-Ile-de France, AP-HP, Université Paris Diderot, Paris, France | [c] Research Memory Center (CMRR), CHU Lyon, Lyon, France | [d] Department of Biology, CHU Besançon, Besançon, France | [e] Department of Neurology, CHU Nancy, Nancy, France | [f] Regional Memory Center (CMRR), CHU Saint-Etienne, Saint Priest en Jarez, France
Correspondence:
[*]
Correspondence to: Eloi Magnin, Department of Neurology, University Hospital, 25000 Besancon, France. Tel.: +33 381668098; Fax: +33 381668470; E-mail: eloi.magnin@laposte.net.
Abstract: Background:Patients with logopenic variant of primary progressive aphasia (lvPPA) display neuropathological differences from typical amnestic Alzheimer’s disease (AD). Objective:The aim of the study was to compare cerebrospinal fluid (CSF) biomarker levels between patients with lvPPA due to AD (lvPPA-AD), non-logopenic forms of AD (nlAD), and amnestic mild cognitive impairment due to AD (aMCI-AD). Methods:CSF biomarker concentrations were assessed in 124 patients divided into three groups matched for age, level of education, center, and disease duration: lvPPA-AD (n = 30), nlAD (n = 67). and aMCI-AD (n = 27). Results:p-Tau181 levels were higher in the lvPPA-AD group than in the aMCI-AD group (p < 0.05). Total tau levels were higher in the lvPPA-AD group versus those in the nlAD (p < 0.05) and aMCI-AD (p < 0.001) groups. Conclusions:These results suggest a more pronounced involvement of a taupathy in lvPPA-AD compared to aMCI-AD and a more important neuronal death in lvPPA-AD than in nlAD or aMCI-AD.
